BioSenic S.A. - Asset Resilience Ratio
BioSenic S.A. (BIOS) has an Asset Resilience Ratio of -3.43% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check BIOS PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2023)
This chart shows how BioSenic S.A.'s Asset Resilience Ratio has changed over time. See BioSenic S.A. (BIOS) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down BioSenic S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BioSenic S.A. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €-322.00K | -3.43% |
| Total Liquid Assets | €-322.00K | -3.43% |
Asset Resilience Insights
- Limited Liquidity: BioSenic S.A. maintains only -3.43% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
BioSenic S.A. Industry Peers by Asset Resilience Ratio
Compare BioSenic S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for BioSenic S.A. (2011–2023)
The table below shows the annual Asset Resilience Ratio data for BioSenic S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 4.16% | €398.00K ≈ $465.30K |
€9.56 Million ≈ $11.18 Million |
+4.54pp |
| 2022-12-31 | -0.38% | €-111.00K ≈ $-129.77K |
€29.32 Million ≈ $34.28 Million |
-6.45pp |
| 2021-12-31 | 6.07% | €1.20 Million ≈ $1.40 Million |
€19.77 Million ≈ $23.12 Million |
+6.69pp |
| 2019-12-31 | -0.63% | €-140.00K ≈ $-163.67K |
€22.39 Million ≈ $26.18 Million |
-1.97pp |
| 2011-12-31 | 1.35% | €203.00K ≈ $237.33K |
€15.05 Million ≈ $17.60 Million |
-- |
About BioSenic S.A.
BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company offers arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops 4P004v which is in Pha… Read more